The Venture Codex

Participated · Seed · Mar 2025

mo:re provides a laboratory platform that automates the planning, culture, and analysis of complex 3D cell culture models. The platform is designed to deliver verifiable, standardized results without requiring expertise in specific organ systems. Led by CEO Lukas Gaats, the company focuses on complex cell culture workflows and commercialization of its system. mo:re raised €2.3M in Seed funding to accelerate commercialization of its platform. The funding will be used to speed the commercialization of the platform for complex cell culture workflows. The company is based in Hamburg, Germany.

Led · Seed · Feb 2024

Colipi develops an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into "climate oil," positioned as a carbon-neutral replacement for palm and crude oil. The company's core technology centers on a patented bioreactor system and a gas fermentation process that it describes as a breakthrough for producing biomaterials at scale. Led by CEO Maximilian Webers, Colipi intends to scale its precision fermentation to a 10 cubic meter pilot and enter the market with climate oil. Management emphasizes competitive pricing and minimal environmental impact, with potential to reduce Scope 3 greenhouse gas emissions for customers. The recent seed financing will support the pilot scale-up and initial market entry plans.

Participated · Seed · Jul 2019

Antibodies.com operates a digital marketplace connecting life scientists with validated antibodies, proteins and immunoassays sold by primary manufacturers. The company launched out of beta in May 2018 and has grown to work with 50+ supply chain partners. It offers a catalogue of 70,000+ research reagents and serves customers across North America and Europe. Customers include large pharmaceutical companies such as GlaxoSmithKline, Glenmark Pharmaceuticals and Merck & Co, as well as academic institutions including MIT, Standard University, the University of Cambridge and the University of Oxford. Antibodies.com plans to use new funding to expand its off-the-shelf reagent catalogue, implement sales and marketing programs to drive customer acquisition, and scale its proprietary AI-assisted "Product Matching" tool. The company recently completed a pre-seed financing to support these growth initiatives.